Haleon (HLN) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Organic Revenue Growth: 3.4% in Q3, with 1.8% from price increases and 1.6% from volume mix.

Reported Revenue Growth: 0.7%, impacted by divestments (-2.3%) and foreign exchange (-0.4%).

Regional Performance:

EMEA and LatAm: 5.3% organic growth.

North America: 0.4% organic growth.

Asia Pacific: 5.1% organic growth.

Oral Health Segment: Grew 6.9%, driven by innovations and geographic expansion.

VMS (Vitamins, Minerals, Supplements): Grew 4.9%, with strong performance from Centrum.

Pain Relief: Grew 3.7%, with Panadol showing high single-digit growth.

Cash Flow and Capital Allocation: Completed GBP 500 million share buyback for 2025.

2Strategic Updates and Business Highlights

Continued rollout of innovation pipeline, with successful launches like Sensodyne Pronamel and Otrivin Nasal Mist.

Focus on premiumization and expanding reach to lower-income consumers, particularly in India and Brazil.

Supply chain productivity initiatives are progressing, with a 19% reduction in SKUs and improved gross margins.

Strong digital growth, particularly in e-commerce, with a 20% increase in online sales.

3Forward Guidance and Outlook

2025 Guidance: Expecting organic revenue growth around 3.5%, assuming a normal cold and flu season.

Anticipate North America to return to growth in 2026, with expectations of a clean inventory position by year-end.

Continued strong growth expected in Asia Pacific, particularly in India and China.

4Bad News, Challenges, or Points of Concern

North America: Facing a challenging consumer environment; Q4 guidance suggests a decline of approximately 1% in organic sales, attributed to tough comparatives and inventory adjustments.

Consumer Behavior: Notable shifts towards larger and lower-priced packs, indicating potential down-trading pressures.

Competitive Pressures: Increased promotional activity in VMS and Respiratory categories due to soft consumption.

Brazil: Macroeconomic challenges impacting consumer spending, with specific weaknesses noted in the EO category.

5Notable Q&A Insights

North America Performance: Sequential improvement attributed to better performance in Oral Health and a reduction in the drag from Smokers' Health. No significant one-off benefits were noted in Q3.

Asia Pacific Growth: Despite a deceleration, double-digit growth in India and mid-single-digit growth in China were highlighted, with expectations for continued momentum.

Pricing Strategy: A modest price increase is set for early November, with expectations of lower elasticity due to market conditions.

Inventory Management: Emphasis on exiting the year with appropriate inventory levels to support growth in 2026. This summary encapsulates Haleon's performance in Q3 2025, highlighting key financial metrics, strategic initiatives, and the outlook for the coming quarters while addressing challenges faced in the current market environment.